Navigation Links
Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
Date:6/27/2012

ients from our Phase 2 study clearly identifies those patients most in need of therapy and most likely to benefit from our potent BAFF inhibitor blisibimod," said Paul F. Truex, Anthera's President and Chief Executive Officer. "Feedback from the EMA Scientific Advice process combined with an End of Phase 2 meeting in the third quarter will form the basis of our final phase 3 study designs."

Table 1:  Response rates for 200mg weekly subcutaneous blisibimod versus placeboEndpoint (Subgroup)12 Week ResponsePlacebo / Active16 Week Response Placebo / Active 20 Week Response Placebo / Active24 Week Response Placebo / ActiveSRI-5

(mITT*)

27.1% / 29.3%

26.8% / 34.8%

31.6% / 44.6%

35.3% / 43.5%SRI-5

(Moderate*)

24.1% / 30.0%

29.3% / 36.0%

31.0% / 44.0%

34.5% / 48.0%SRI-5

(Severe*)

27.7% / 37.5%

34.0% / 41.7%

36.2% / 52.1%

40.4% / 54.2%* mITT:  Lupus, SELENA/SLEDAI >6, seropositive* Moderate Subgroup:  Lupus, SELENA/SLEDAI >8, seropositive, receiving steroids* Severe Subgroup:  Lupus, SELENA/SLEDAI >10, seropositive, receiving steroidsThe pre-specified primary efficacy endpoint, clinical improvement at 24 weeks in the SLE responder index for the pooled blisibimod dose groups, was not met due to a lack of clinical efficacy in the 100mg weekly and 200mg monthly dose groups.  All doses of blisibimod demonstrated consistent serological response including reductions of B-cells, ds-DNA and improvements in both complement C3 and C4.  Blisibimod was safe and well-tolerated at all dose levels with no meaningful imbalances in serious adverse events.  A single suicide attempt and a non-fatal single tuberculosis infection were seen in the placebo group.  There were seven deaths during the study - three in placebo and four blisibimod. 

Following a submission in April of 2012 the Company r
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Neuralstem Updates ALS Stem Cell Trial Progress
5. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
6. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
7. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
8. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
9. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
10. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS ... duties to shareholders. On January 21, 2015, ... that Advaxis had misrepresented the clinical data for its ...
(Date:1/23/2015)... 23, 2015  HyGreen, Inc., a leader in hand hygiene ... RCA Medical, a subsidiary of Ascendis Health Limited, in ... Each year, hundreds of millions of patients around the ... are transmitted from patient to patient via the unwashed ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has repositioned ... market share and grab a foothold in the hydroponic, hemp ... capabilities and a presence in the sector, and recently partnering ... growth of hemp and medical marijuana, iMD is committing to ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2HyGreen Partners with RCA Medical in Johannesburg, South Africa 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... Ill., April 19, 2011 Sysmex, a global ... systems technology, announced today an amended distributorship agreement ... automatically renews for up to four successive one-year ... including the Sysmex pocH-100 i™ , Sysmex KX-21N™, ...
... Premier Research Group Limited announces the re-branding of ... Research Company. With the continued growth in clinical development ... the medical device industry, Premier Research recognises this sector ... D-TARGET was founded in 1997 and acquired ...
Cached Medicine Technology:Sysmex America Signs Distributorship Agreement With LABSCO 2Premier Research Re-brands its Medical Device Business Unit to D-TARGET 2
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting ... auto insurance policy . , Some types of vehicles cannot ... the newly released blog post to see if their vehicle qualifies ... vehicles are some of the cars that cannot be covered by ...
(Date:1/22/2015)... 22, 2015 Step into a macabre ... Science Museum of Virginia. Wicked Plants, the Museum’s latest ... unearths 75 poisonous, carnivorous and diabolical plants inside of ... to uncover the biochemical, physical and neurological processes between ...
(Date:12/26/2014)... The US represents the largest market for CRC across the ... that sales of branded therapies were $2.23 billion. The US ... of the disease, high drug treatment rate, and higher drug ... of CRC therapies over the forecast period will be driven ...
Breaking Medicine News(10 mins):Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... researchers have identified the first biomarker of graft-versus-host disease ... blood test that should solve a treatment dilemma facing ... marrow transplants. The biomarker also makes it possible to ... graft-versus-host disease, or GVHD. GVHD is a serious, ...
... continue climbing to exhaustion may be the only determinant of ... the University of Granada, the objective of which is to ... of sport, shows this to be the case. ... fat percentage and grip strength. Furthermore, existing research was based ...
... CT, ultrasound imaging and MRI, doctors have long been able ... patient,s body, and now a Texas A&M University mathematician is ... , The professor, Peter Kuchment, a leading researcher in mathematical ... process for detecting cancer and many other diseases. , When ...
... Researchers ... working to reduce the radiation exposure associated with CT imaging. A study featured on the ... cancer from CT imaging. , ... Loma Linda, CA (Vocus) January 7, 2010 -- Researchers from the department of radiology and ...
... ... ... College of American Pathologists (CAP) released the new CAP electronic Cancer Checklists (CAP eCC)—the XML ... enhance and advance cancer reporting., , , , ,The latest CAP eCC release contains all ...
... ... , ... 8, 2010 -- After more than 20 years with very little innovation, the world of ... tool for cast removal. , , , , ,With an operating sound level just above ...
Cached Medicine News:Health News:Blood test could improve graft-versus-host disease treatment 2Health News:Blood test could improve graft-versus-host disease treatment 3Health News:How high can a climber go? 2Health News:Texas A&M prof working on new ways to see through the human body 2Health News:New Low Dose CT Protocols for Stone Detection may Hold Key to Reducing Cancer Risk from Radiation 2Health News:New Low Dose CT Protocols for Stone Detection may Hold Key to Reducing Cancer Risk from Radiation 3Health News:College of American Pathologists Releases New Updated CAP Electronic Cancer Checklist (CAP eCC) 2Health News:College of American Pathologists Releases New Updated CAP Electronic Cancer Checklist (CAP eCC) 3Health News:College of American Pathologists Releases New Updated CAP Electronic Cancer Checklist (CAP eCC) 4Health News:New 'Kid-Friendly' Cast Removal Tool Now at Sanford 2
Landolt hypophysectomie instrument, spoon, bayonet-shaped, flexible....
Cushing pituitary scoop, malleable, silver-plated....
... Cougar is an Anterior Spinal Implant system. ... approximating that of cortical bone. The result ... requirements of anterior column support, while optimizing ... sharing design. Incorporates an anatomic design with ...
... The Stackable Cage System provides anterior column ... total vertebrectomies from T1 to L5. The ... Carbon Fiber Polymer cages that are stacked ... needs. The Peek Carbon Fiber Reinforced Polymer ...
Medicine Products: